Recent Articles from MarketBeat

MarketBeat is an American financial media company headquartered in Sioux Falls, South Dakota, founded in 2011 by Matthew Paulson as Analyst Ratings Network before rebranding in 2015. The company operates an online platform that delivers real-time financial data, market analysis, and news, aiming to empower individual investors with tools to make informed trading decisions.

Lloyds Banking Group Sees Slower Interest Income Growth in 2027 as Competition Bitesmarketbeat.com
Lloyds Banking Group (NYSE:LYG) expects net interest income to grow in the mid-single digits in 2027, slowing from this year’s pace as competition for loans and deposits continues, Chief Financial Officer William Chalmers said. Speaking with JPMorgan Executive Director Sheel Shah, Chalmers said the
Via MarketBeat · November 18, 2026
Danaher Targets Faster Growth With Acquisitions, AI and a Diagnostics Pushmarketbeat.com
Danaher (NYSE:DHR) is focusing on commercial execution, innovation and acquisitions as it seeks faster core growth and market-share gains, company leader Julie said during a discussion with Tycho Peterson of the Life Science team. Julie, who was identified only by her first name in the transcript,
Via MarketBeat · November 18, 2026
Severn Trent H1 Earnings Call Highlightsmarketbeat.com
Severn Trent (LON:SVT) reported a 13% increase in first-half profit before interest and tax and raised the lower end of its annual capital investment guidance after spending more than £1 billion on projects across its region. Adjusted earnings per share rose more than 17% to £1.188, while revenue i
Via MarketBeat · November 18, 2026
DexCom Sees Record New Patients in 2026 as Medicare Coverage Decision Loomsmarketbeat.com
DexCom (NASDAQ:DXCM) expects a record number of new patients in 2026 and is preparing for a potential expansion of Medicare coverage for continuous glucose monitoring, executives said during a discussion hosted by Jefferies. CEO Jake Leach said the company has raised its outlook to the top end of t
Via MarketBeat · November 18, 2026
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectationsmarketbeat.com
MannKind (NASDAQ:MNKD) is focusing on the launch of its FUROSCIX ReadyFlow autoinjector, pediatric AFREZZA and the development of inhaled nintedanib, CEO Michael Castagna said at the UBS Biopharma Conference in London. Castagna said MannKind expects to be profitable next year after a period of inve
Via MarketBeat · November 18, 2026
Iron Mountain Sees Billion-Dollar Growth in Data Centers and IT Asset Servicesmarketbeat.com
Iron Mountain (NYSE:IRM) is counting on cross-selling digital services, asset lifecycle management and data center capacity to its established customer base as it expands beyond records storage, Chief Financial Officer Barry Hytinen said at a J.P. Morgan services event. Hytinen said the company ser
Via MarketBeat · November 17, 2026
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surgemarketbeat.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) is pursuing growth from its DAYBUE and NUPLAZID franchises while advancing neurological and psychiatric drug candidates and looking for external deals, CEO Catherine Owen Adams said at a UBS-hosted event. The company recently reported quarterly revenue of $342 m
Via MarketBeat · November 17, 2026
ZTO Express (Cayman) Q3 Earnings Call Highlightsmarketbeat.com
ZTO Express (Cayman) (NYSE:ZTO) reported higher third-quarter revenue and operating profit as parcel volumes grew faster than the broader industry, and the delivery company maintained its full-year volume guidance despite slowing sector growth. Revenue rose 21% year over year to CNY 14.4 billion in
Via MarketBeat · November 17, 2026
GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast Gapmarketbeat.com
GSK (NYSE:GSK) Chief Financial Officer Julie Brown said oncology products could help close the gap between analysts’ sales expectations and the company’s target of more than £40 billion in annual sales by 2031, as it accelerates drug development and cuts costs. Speaking at the 2026 U.K. Leaders Con
Via MarketBeat · November 17, 2026
Air Canada Sees Full Fuel Cost Recovery in 2027 After $1 Billion Hit This Yearmarketbeat.com
Air Canada (TSE:AC) expects to recover the full cost of fuel through fares in 2027, assuming prices follow their current downward-sloping forward curve without another significant spike, Executive Vice President and Chief Financial Officer John Di Bert said at an investor event. Di Bert said the ai
Via MarketBeat · November 17, 2026
Syntec Optics Q3 Earnings Call Highlightsmarketbeat.com
Syntec Optics (NASDAQ:OPTX) reported record third-quarter 2026 revenue of approximately $8.5 million, up 23% from a year earlier, as growth in defense and space products helped the company return to profitability. Net income was approximately $0.2 million, or $0.01 per basic and diluted share, comp
Via MarketBeat · November 17, 2026
NVIDIA Q3 Earnings Call Highlightsmarketbeat.com
NVIDIA (NASDAQ:NVDA) raised its fiscal 2028 revenue growth forecast and reported record quarterly revenue as its Vera Rubin platform ramped up, even as the company searches for a permanent chief executive following Jensen Huang’s resignation. Revenue reached $116 billion in the third quarter of fis
Via MarketBeat · November 17, 2026
Dolby Laboratories Q4 Earnings Call Highlightsmarketbeat.com
Dolby Laboratories (NYSE:DLB) expects fiscal 2027 revenue to remain roughly flat at $1.42 billion as lower device shipments and comparisons with unusually strong licensing recoveries offset growth in its automotive and video distribution businesses. The outlook follows a fiscal 2026 in which revenu
Via MarketBeat · November 17, 2026
NIKE Sees Revenue Falling Through 2028, Targets $5 Billion Rebound by 2031marketbeat.com
NIKE (NYSE:NKE) expects revenue to decline through fiscal 2028 before returning to market-level growth in fiscal 2029, as the company resets its sportswear business, reduces discounting and works to stabilize sales in Greater China. At its investor day, the company outlined a plan to add approximat
Via MarketBeat · November 17, 2026
What 5E Advanced Materials (FEAM) Said on Its Q1 Earnings Callmarketbeat.com
5E Advanced Materials (NASDAQ:FEAM) is working to increase borate production and establish export sales after completing its acquisition of Searles Valley Minerals on October 1, one day after the end of its fiscal first quarter. Chief Executive Officer Paul Weibel said the acquisition turned the co
Via MarketBeat · November 17, 2026
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019marketbeat.com
Biogen (NASDAQ:BIIB) expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return to revenue growth, President and Head of North America Alisha Alaimo said at a Jefferies conference
Via MarketBeat · November 17, 2026
BlackBerry’s QNX Backlog Rises $250 Million as Higher-Priced Auto Software Gains Tractionmarketbeat.com
BlackBerry (NYSE:BB) executives said growth in the company’s QNX automotive software business is being supported by a rising royalty backlog, higher-priced products and the expected expansion of high-performance computing in vehicles. At a discussion hosted by RBC technology analyst Paul Treiber, C
Via MarketBeat · November 17, 2026
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trialmarketbeat.com
Novavax (NASDAQ:NVAX) is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi’s development of a combination COVID-19 and flu shot, executives said at the Jefferies 2026 Global Healthcare Conference in London. CE
Via MarketBeat · November 17, 2026
Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loommarketbeat.com
Vertex Pharmaceuticals (NASDAQ:VRTX) is approaching a Nov. 30 U.S. regulatory decision for its kidney disease drug povetacicept, with a series of clinical readouts expected through 2027 as the company seeks to expand beyond its cystic fibrosis business. Speaking at a Jefferies fireside chat in Lond
Via MarketBeat · November 17, 2026
Powell Industries Q4 Earnings Call Highlightsmarketbeat.com
Powell Industries (NASDAQ:POWL) reported record fiscal 2026 revenue, earnings and orders, as demand from liquefied natural gas projects and data centers helped push its backlog to $2.7 billion. The electrical equipment maker said fourth-quarter revenue rose 33% to $397 million, while net income inc
Via MarketBeat · November 17, 2026
Caterpillar Sees a Bright 2027 as Compact Equipment and Rental Expansion Gains Groundmarketbeat.com
Caterpillar (NYSE:CAT) is expanding its compact equipment and rental businesses to reach smaller contractors and win more large projects, Construction Industries Group President Rod Shurman said during an investor discussion at a Cat Compact store in North Carolina. Shurman said the company is gain
Via MarketBeat · November 17, 2026
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approvalmarketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference. Chief Financial Officer
Via MarketBeat · November 17, 2026
What Midera Food Processing (MFP) Said on Its Q3 Earnings Callmarketbeat.com
Midera Food Processing (NASDAQ:MFP) raised its 2026 sales and adjusted earnings outlook after reporting double-digit third-quarter sales growth and stronger margins in its first full quarter as an independent public company. The food-processing equipment maker reported net sales of $228.9 million,
Via MarketBeat · November 17, 2026
What Oaktree Specialty Lending (OCSL) Said on Its Q4 Earnings Callmarketbeat.com
Oaktree Specialty Lending (NASDAQ:OCSL) reported lower adjusted net investment income for its fiscal fourth quarter and full year, as a smaller average portfolio weighed on investment income. The lender said it plans to focus on resolving troubled investments and putting capital to work in performin
Via MarketBeat · November 17, 2026
NVIDIA's Turbulence Could Have Ripple Effects Across Quantum Computingmarketbeat.com
Via MarketBeat · November 17, 2026
What Energizer (ENR) Said on Its Q4 Earnings Callmarketbeat.com
Energizer (NYSE:ENR) expects free cash flow to rise to approximately $300 million in fiscal 2027, as lower restructuring costs and capital spending help the battery and auto care company direct more cash toward debt reduction. The outlook follows a fiscal 2026 in which free cash flow more than trip
Via MarketBeat · November 17, 2026
What Home Depot (HD) Said on Its Q3 Earnings Callmarketbeat.com
Home Depot (NYSE:HD) reported third-quarter sales growth of 4.9% and updated its full-year outlook after repair and remodeling demand helped comparable sales rise at their fastest pace in four years. The retailer posted sales of $43.4 billion, while companywide and U.S. comparable sales each increa
Via MarketBeat · November 17, 2026
What fuboTV (FUBO) Said on Its Q4 Earnings Callmarketbeat.com
fuboTV (NYSE:FUBO) reported positive fourth-quarter free cash flow and said it will stop reporting quarterly subscriber figures as it shifts its focus toward revenue and profitability following its combination with Hulu + Live TV. The company reaffirmed its target of at least $300 million in adjust
Via MarketBeat · November 17, 2026
Euroseas Q3 Earnings Call Highlightsmarketbeat.com
Euroseas (NASDAQ:ESEA) reported lower third-quarter revenue and net income as it operated a smaller fleet, while raising its quarterly dividend and extending charter coverage for several vessels. The container ship owner reported net revenue of $54.1 million for the quarter, down 5% from $56.9 mill
Via MarketBeat · November 17, 2026
Banking on AI: Can Upstart's New Bank Plan Turn Its Stock Around?marketbeat.com
Via MarketBeat · November 17, 2026
Spire Q4 Earnings Call Highlightsmarketbeat.com
Spire (NYSE:SR) reported a 20% increase in fiscal 2026 adjusted earnings per share from continuing operations and outlined a multiyear growth plan, even as regulatory outcomes and weather-related revenue uncertainty prompted the natural gas utility to reduce its near-term guidance. The company earn
Via MarketBeat · November 17, 2026
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugsmarketbeat.com
Gilead Sciences (NASDAQ:GILD) expects HIV and oncology to drive growth through the rest of the decade while it builds an inflammation business for the 2030s, executives said at a London healthcare conference. Chairman and CEO Dan O’Day said the company was coming off its strongest growth in more th
Via MarketBeat · November 17, 2026
What Amer Sports (AS) Said on Its Q3 Earnings Callmarketbeat.com
Amer Sports (NYSE:AS) raised its full-year revenue and earnings guidance after reporting 24% sales growth in the third quarter of 2026, driven by demand for Arc'teryx apparel, Salomon footwear and Wilson tennis products. Adjusted diluted earnings per share rose to $0.42 from $0.33 a year earlier, w
Via MarketBeat · November 17, 2026
Klarna Group Q3 Earnings Call Highlightsmarketbeat.com
Klarna Group (NYSE:KLAR) expects to report positive net income in the fourth quarter after narrowing its loss in the third quarter of 2026, executives said on the company’s earnings call. Growth in U.S. financing and card spending helped lift transaction margin dollars, a key measure of profitabilit
Via MarketBeat · November 17, 2026
MYT Netherlands Parent B.V. Q1 Earnings Call Highlightsmarketbeat.com
MYT Netherlands Parent B.V. (NYSE:MYTE), operating as LuxExperience, raised its fiscal 2027 profitability outlook after reporting faster sales growth and a fourth consecutive quarter of positive adjusted earnings before interest, taxes, depreciation and amortization. For the first quarter ended Sep
Via MarketBeat · November 17, 2026
What Research Solutions (RSSS) Said on Its Q1 Earnings Callmarketbeat.com
Research Solutions (NASDAQ:RSSS) reported lower revenue for its fiscal 2027 first quarter as weakness in document delivery and its consumer business offset growth in corporate subscriptions. Management said demand for its artificial intelligence research tools is growing, including a $1 million annu
Via MarketBeat · November 17, 2026
AECOM Q4 Earnings Call Highlightsmarketbeat.com
AECOM (NYSE:ACM) expects revenue and earnings to grow in fiscal 2027, supported by a record backlog, even as two challenging construction management projects are expected to weigh on cash flow in the first half of the year. The infrastructure consulting company forecast net service revenue growth o
Via MarketBeat · November 17, 2026
What Walt Disney (DIS) Said on Its Q4 Earnings Callmarketbeat.com
Walt Disney (NYSE:DIS) reported fiscal 2026 growth in revenue, operating income and adjusted earnings per share, while outlining plans to increase content spending and generate approximately $3 billion in annual run-rate savings by fiscal 2029. CEO Josh D'Amaro said on the company’s fiscal fourth-q
Via MarketBeat · November 17, 2026
What Elbit Systems (ESLT) Said on Its Q3 Earnings Callmarketbeat.com
Elbit Systems (NASDAQ:ESLT) reported a 17.2% increase in third-quarter revenue and a record $33 billion backlog, as demand for ammunition, electronic warfare systems and other defense products supported growth. The company said it expects revenue to grow in the high teens and margins to expand furth
Via MarketBeat · November 17, 2026
Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Yearmarketbeat.com
Via MarketBeat · November 17, 2026
The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watchmarketbeat.com
Via MarketBeat · November 17, 2026
Viking Q3 Earnings Call Highlightsmarketbeat.com
Viking (NYSE:VIK) reported higher third-quarter revenue but lower adjusted earnings as historically low water levels disrupted European river cruises, prompting guest cancellations and additional costs. Revenue rose 9.2% from a year earlier to $2.2 billion, supported by fleet expansion and higher r
Via MarketBeat · November 17, 2026
Grupo Supervielle Q3 Earnings Call Highlightsmarketbeat.com
Grupo Supervielle (NYSE:SUPV) lowered its 2026 profitability and loan growth outlook after third-quarter earnings fell from the prior quarter, as lower asset yields compressed lending spreads and a softer economy weighed on fees. The Argentine financial services group reported third-quarter net inc
Via MarketBeat · November 17, 2026
ServiceNow Sees AI Usage Surge as It Raises Annual Contract Value Target to $1.7 Billionmarketbeat.com
ServiceNow (NYSE:NOW) is seeing growing customer use of its artificial intelligence tools, including products that automate finance, procurement and human resources work, according to Josh Kahn, the company’s senior vice president and general manager of Core Business Workflows. Speaking at the 2026
Via MarketBeat · November 17, 2026
OneWater Marine Q4 Earnings Call Highlightsmarketbeat.com
OneWater Marine (NASDAQ:ONEW) reported higher adjusted earnings for fiscal 2026 despite a decline in revenue, as improved margins and lower expenses helped offset a softer boat market. The company forecast further growth in adjusted EBITDA for fiscal 2027 while assuming a flat industry in unit terms
Via MarketBeat · November 17, 2026
What JD.com (JD) Said on Its Q3 Earnings Callmarketbeat.com
JD.com (NASDAQ:JD) returned to revenue growth in the third quarter of 2026 as stronger general merchandise and advertising sales, along with narrower losses in new businesses, helped lift adjusted earnings. Revenue rose 3.5% from a year earlier to CNY 310 billion, while non-GAAP net income attribut
Via MarketBeat · November 17, 2026
Griffon Q4 Earnings Call Highlightsmarketbeat.com
Griffon (NYSE:GFF) expects revenue and adjusted earnings to remain flat in fiscal 2027 after a year of asset transactions, debt reduction and shareholder returns transformed the company into a building products business. The company forecast fiscal 2027 revenue of $1.85 billion and adjusted EBITDA
Via MarketBeat · November 17, 2026
What Similarweb (SMWB) Said on Its Q3 Earnings Callmarketbeat.com
Similarweb (NYSE:SMWB) reported third-quarter revenue growth of 15.6% and its first positive GAAP net income, as AI-related deals drove much of the annual recurring revenue added during the period. The company also raised its full-year revenue and adjusted operating profit guidance. Revenue rose to
Via MarketBeat · November 17, 2026
What Opera (OPRA) Said on Its Q3 Earnings Callmarketbeat.com
Opera (NASDAQ:OPRA) reported third-quarter revenue growth of 20% and raised the low end of its full-year revenue forecast, as advertising and query revenue increased despite changes in the e-commerce and internet search markets. Revenue rose to $182.8 million, while adjusted earnings before interes
Via MarketBeat · November 17, 2026
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Callmarketbeat.com
NRx Pharmaceuticals (NASDAQ:NRXP) reported higher third-quarter patient revenue and a narrower net loss, while outlining plans to commercialize its first approved drug and advance experimental treatments for depression and other conditions. The company’s preservative-free ketamine product received
Via MarketBeat · November 17, 2026
Tyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend Investorsmarketbeat.com
Via MarketBeat · November 17, 2026
3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stakemarketbeat.com
Via MarketBeat · November 17, 2026
Illumina Sees Strong Clinical Demand, but Research Recovery Remains in Questionmarketbeat.com
Illumina (NASDAQ:ILMN) is seeing strong demand for its sequencing instruments from clinical customers, while remaining cautious about a recovery in research spending, Chief Financial Officer Ankur Dhingra said at a company news event. Dhingra said the company was making progress toward a goal, laid
Via MarketBeat · November 17, 2026
Tencent Music Entertainment Group Q3 Earnings Call Highlightsmarketbeat.com
Tencent Music Entertainment Group (NYSE:TME) reported a 6% increase in third-quarter revenue as its newly consolidated Ximalaya audio business, merchandise sales and live performances helped offset pressure on its traditional advertising business. The company generated revenue of CNY 8.9 billion in
Via MarketBeat · November 17, 2026
Tyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautiousmarketbeat.com
Via MarketBeat · November 17, 2026
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwindmarketbeat.com
Gilead Sciences (NASDAQ:GILD) expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV treatment Biktarvy creates an anticipated $1.5 billion headwind in 2028, Chief Financial Officer Andy Di
Via MarketBeat · November 17, 2026
What Weibo (WB) Said on Its Q3 Earnings Callmarketbeat.com
Weibo (NASDAQ:WB) reported a 7% decline in third-quarter revenue as cautious advertisers and a difficult comparison with last year’s food-delivery marketing surge outweighed spending tied to new product launches and the World Cup. Revenue totaled $410.2 million, including $344.1 million in advertis
Via MarketBeat · November 17, 2026
Microsoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be Buildingmarketbeat.com
Via MarketBeat · November 17, 2026
MongoDB's Biggest Advantage May Be GitLab's Biggest Weaknessmarketbeat.com
Via MarketBeat · November 17, 2026
HUYA Q3 Earnings Call Highlightsmarketbeat.com
HUYA (NYSE:HUYA) reported higher third-quarter revenue and returned to operating profitability as growth in game-related services and advertising offset a decline in live-streaming revenue. Total net revenue rose 3.8% from a year earlier to CNY 1.75 billion. Operating income was approximately CNY 1
Via MarketBeat · November 17, 2026
CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Buildmarketbeat.com
CRISPR Therapeutics (NASDAQ:CRSP) is preparing to advance several experimental treatments toward late-stage trials, with executives pointing to upcoming data from its cardiovascular and cell therapy programs and growing demand for its commercial product, CASGEVY. CEO Sam Kulkarni said during a Jeff
Via MarketBeat · November 17, 2026
What Trifast (TRI) Said on Its H1 Earnings Callmarketbeat.com
Trifast (LON:TRI) lowered its outlook for the second half of fiscal 2027, citing weaker U.S. automotive demand, disruption linked to the Middle East conflict and competitive pressure on home appliance customers. The revised guidance came as the company reported higher underlying profit for the firs
Via MarketBeat · November 17, 2026
Imperial Brands H2 Earnings Call Highlightsmarketbeat.com
Imperial Brands (LON:IMB) reported a sixth consecutive year of growth in tobacco and next-generation product revenue and adjusted operating profit, as higher cigarette prices offset falling volumes and its newer nicotine products gained market share. For fiscal 2026, tobacco and next-generation pro
Via MarketBeat · November 17, 2026
What Diploma (DPLM) Said on Its H2 Earnings Callmarketbeat.com
Diploma (LON:DPLM) reported 45% earnings per share growth for fiscal 2026 and forecast another year of revenue and earnings growth, although management expects margins and the pace of organic growth to moderate. The company said revenue rose 21%, including 15% organic growth and a 6% contribution f
Via MarketBeat · November 17, 2026
Pfizer CEO Sees Growth Beyond Patent Cliff, Highlights Monthly Obesity Drug Ambitionsmarketbeat.com
Pfizer (NYSE:PFE) expects recently launched medicines and a growing pipeline to help it emerge from a period of patent expirations with high single-digit growth, CEO Albert Bourla said at the Jefferies London Healthcare Conference. Bourla said the loss-of-exclusivity period is expected to last anot
Via MarketBeat · November 17, 2026
What FirstGroup (FGP) Said on Its H1 Earnings Callmarketbeat.com
FirstGroup (LON:FGP) said it expects to maintain adjusted earnings per share for its 2027 financial year despite a first-half decline, as bus profit growth was offset by costs for a new rail service and competition on the East Coast Main Line. The U.K. transport operator reported a 21.2% increase i
Via MarketBeat · November 17, 2026
GSK Targets £40 Billion in Sales as HIV Patent Cliff Loomsmarketbeat.com
GSK (NYSE:GSK) expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology business and continued dealmaking, President of Business Development David Redfern said at the Jefferies Healthcare Conference. Redfern said the
Via MarketBeat · November 17, 2026
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filingmarketbeat.com
Cytokinetics (NASDAQ:CYTK) executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic cardiomyopathy. Speaking at the UBS Biopharma Conference, President and CEO Robert Blum also announced th
Via MarketBeat · November 17, 2026
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launchesmarketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Biopharma Conference. CEO Emil Kakkis said the company is heading toward $1 billio
Via MarketBeat · November 17, 2026
Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Aheadmarketbeat.com
Insmed (NASDAQ:INSM) expects its bronchiectasis drug BRINSUPRI to generate $1.35 billion to $1.4 billion in its first full year of launch, Chief Executive Officer Will Lewis said, as the company looks to reach more patients and expand its pipeline. Speaking at the Jefferies Global Healthcare Confer
Via MarketBeat · November 17, 2026
Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filingmarketbeat.com
Solid Biosciences (NASDAQ:SLDB) plans to meet with the U.S. Food and Drug Administration before the end of 2026 to discuss a potential accelerated approval pathway for its Duchenne muscular dystrophy gene therapy, CEO Bo Cumbo said at a Jefferies fireside chat. The company has dosed 53 patients wit
Via MarketBeat · November 17, 2026
Rollins Tests AI Marketing as Digital Leads Drop and Growth Target Faces Uncertaintymarketbeat.com
Rollins (NYSE:ROL) is testing new marketing approaches as consumers increasingly use artificial intelligence platforms to find pest-control providers, Chief Financial Officer Will Harkins said at a discussion hosted by RBC analyst Ashish Sabadra. Harkins said the company has brought in multiple mar
Via MarketBeat · November 17, 2026
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quartermarketbeat.com
United Therapeutics (NASDAQ:UTHR) is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory and clinical milestones at the UBS London Healthcare Conference. The company r
Via MarketBeat · November 16, 2026
Agora Q3 Earnings Call Highlightsmarketbeat.com
Agora (NASDAQ:API) reported third-quarter 2026 revenue of $42.1 million, up 19% from a year earlier, as growth in its real-time engagement business and increasing contributions from conversational artificial intelligence products helped drive a third consecutive quarter of accelerating revenue growt
Via MarketBeat · November 16, 2026
Yalla Group Q3 Earnings Call Highlightsmarketbeat.com
Yalla Group (NYSE:YALA) reported a modest increase in third-quarter revenue as new games began contributing to sales, but higher marketing and development expenses weighed on earnings. Management said it expects the gaming business to drive double-digit revenue growth in 2027 while warning that prof
Via MarketBeat · November 16, 2026
Articles from MarketBeat | FWNBC